Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
To conduct a proof of concept study in patients with mild to moderate Alzheimer's Disease in
order to determine if there is less global brain atrophy over one year, as measured by
ventricular enlargement as a primary outcome measure, when patients are randomized to
treatment with an angiotensin receptor blocker (ARB) compared to an angiotensin converting
enzyme inhibitor (ACEI).
Phase:
Phase 2
Details
Lead Sponsor:
Dr. Sandra E Black Sunnybrook Health Sciences Centre
Collaborators:
Alzheimer's Drug Discovery Foundation Alzheimer’s Drug Discovery Foundation Weston Brain Institute